Recruiting Clinical Trials

Displaying 1 - 10 of 201 result(s)
Study Title Condition Phase Location
A Multicenter Open-label Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine (GEP-NET) Tumors, Pheochromocytoma and Paragangliomas (PPGL) Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma Phase 2
  • Country: 
    United States
  • Country: 
    France
  • Country: 
    Poland
  • Country: 
A Three-period Multicenter Study, With a Randomized-withdrawal, Double-blinded, Placebo-controlled Design in Period 2 to Evaluate the Clinical Efficacy, Safety, and Tolerability of MAS825 in NLRC4-GOF Patients NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis) Phase 2
  • Country: 
    United States
  • Country: 
    Czech Republic
  • Country: 
    France
  • Country: 
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients (Prevention of Relapses and Delay of Progression of Physical Disability in Secondary Progressive Multiple Sclerosis) Secondary Progressive Multiple Sclerosis (SPMS) Not Given
  • Country: 
    Japan
A Randomized, Four-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-articular Canakinumab Followed by Intra-articular LNA043 in Patients With Knee Osteoarthritis Knee Osteoarthritis Phase 2
  • Country: 
    United States
Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Adolescents (12 to Less Than 18 Years) With Heterozygou ... Heterozygous Familial Hypercholesterolemia Phase 3
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Brazil
  • Country: 
Special Drug Use Surveillance for Entresto Tablets (Chronic Heart Failure, CLCZ696B1401) Chronic Heart Failure Not Given
  • Country: 
    Japan
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen (Relapsing-remitting Multiple Sclerosis and Active Secondary Progressive Multiple Sclerosis) Relapsing-remitting Multiple Sclerosis, Active Secondary Progressive Multiple Sclerosis Not Given
  • Country: 
    Japan
Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma Phase 4
  • Country: 
    United States
  • Country: 
    Argentina
  • Country: 
    Austria
  • Country: 
A Randomized, Multi-center, Subject and Investigator-blinded, Placebo-controlled, Parallel-group Study to Assess the Efficacy Safety and Tolerability of LYS006 in Patients With Mild to Moderate Ulcerative Colitis Colitis, Ulcerative Phase 2
  • Country: 
    Bulgaria
  • Country: 
    Czech Republic
  • Country: 
    Germany
  • Country: 
A Subject and Investigator Blinded, Randomized, Placebo-controlled, Repeat-dose, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis Pulmonary Sarcoidosis Phase 2
  • Country: 
    United States
  • Country: 
    Czech Republic
  • Country: 
    Denmark
  • Country: